Hypercholesterolemia, although a modifiable risk factor for cardiovascular disease, is still one of the leading causes of death among older people in western countries. The use of statins among cholesterol reducing agents in both primary and secondary prevention has not been extensively studied in older patients in contrast to middle-aged patients. Despite a growing body of evidence in secondary prevention, statins are still under utilized in older patients with established vascular disease. On the other hand, the benefits of statins in primary prevention are not so clear. Therefore, the systematic use of statins in older patients with hypercholesterolemia needs to be further investigated
The elderly population is increasing worldwide, with subjects > 65 years of age constituting the fas...
Background: Aging is a major risk factor for atherosclerotic cardiovascular diseases (CVD) and death...
Objective Statins have been shown to be beneficial for the prevention of cardiovascular events. In e...
Hypercholesterolemia, although a modifiable risk factor for cardiovascular disease, is still one of ...
Purpose of ReviewHypercholesterolemia and statin treatment are nowadays common among people older th...
Elderly population is increasing rapidly together with the incidence of cardiovascular diseases (CVD...
Abstract Purpose of Review: Hypercholesterolemia and statin treatment are nowadays common among peo...
Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death worldwide. High level...
Cardiovascular disease (CVD) is a major contributor to morbidity and mortality worldwide. An abundan...
The number of the elderly individuals is steeply increasing, and their absolute cardiovascular risk ...
Whether to treat older adults with statin medicationsfor primary prevention of cardiovascular events...
International audienceStatin prescription in persons older than 75 years or with frailty signs ă rai...
BACKGROUND AND AIMS: Limited data is available on the benefit of statin for primary prevention in th...
Background: Current evidence from randomized controlled trials on statins for primary prevention of ...
Therapy of dyslipidemia in the elderly and the oldest old remains controversial. Several studies hav...
The elderly population is increasing worldwide, with subjects > 65 years of age constituting the fas...
Background: Aging is a major risk factor for atherosclerotic cardiovascular diseases (CVD) and death...
Objective Statins have been shown to be beneficial for the prevention of cardiovascular events. In e...
Hypercholesterolemia, although a modifiable risk factor for cardiovascular disease, is still one of ...
Purpose of ReviewHypercholesterolemia and statin treatment are nowadays common among people older th...
Elderly population is increasing rapidly together with the incidence of cardiovascular diseases (CVD...
Abstract Purpose of Review: Hypercholesterolemia and statin treatment are nowadays common among peo...
Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death worldwide. High level...
Cardiovascular disease (CVD) is a major contributor to morbidity and mortality worldwide. An abundan...
The number of the elderly individuals is steeply increasing, and their absolute cardiovascular risk ...
Whether to treat older adults with statin medicationsfor primary prevention of cardiovascular events...
International audienceStatin prescription in persons older than 75 years or with frailty signs ă rai...
BACKGROUND AND AIMS: Limited data is available on the benefit of statin for primary prevention in th...
Background: Current evidence from randomized controlled trials on statins for primary prevention of ...
Therapy of dyslipidemia in the elderly and the oldest old remains controversial. Several studies hav...
The elderly population is increasing worldwide, with subjects > 65 years of age constituting the fas...
Background: Aging is a major risk factor for atherosclerotic cardiovascular diseases (CVD) and death...
Objective Statins have been shown to be beneficial for the prevention of cardiovascular events. In e...